Carolinas HealthCare System

Research and Clinical Trials

Leukemia, not otherwise specified 

Brief Description Principal Investigator
Primary: To determine the safety, tolerability, DLT and combination maximum tolerated dose (combination MTD) of
urelumab in combination with rituximab in subjects with relapsed/refractory B-NHL (including FL and DLBCL) or
Secondary Objectives:
1) To characterize the preliminary multidose PK profile of urelumab in combination with rituximab in subjects with
relapsed/refractory B-NHL (including FL and DLBCL) or CLL.
2) To characterize the immunogenicity of urelumab in combination with r
Ghosh, Nilanjan 
To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone.
The primary goal in this trial is to prevent relapse. AALL1231 will test two major strategies to meet this goal: (1) to modify the existing chemotherapy platform to mirror the most efficacious backbone that has been tested in Phase 3 trials; and, (2) to randomize patients to receive/not receive a novel agent (bortezomib), with strong b
Kaplan, Joel Adam 
To determine the ability of CD34+ cell selection using the CliniMACS® device as the sole
GVHD prophylaxis to prevent severe (grade III-IV) acute GVHD in recipients of
alternative donor (mismatched related donor and unrelated donor) hematopoietic stem
cell transplants.
Gilman, Andrew Lee 
To collect high quality specimens from patients with hematologic disorders and normal volunteers.
Future specimen analyses will be performed to determine the differences between sick and normal cells. Data used for these comparisons will include, but are not limited to: gene expression data, DNA, RNA, epigenetics, proteomics, metabolomics, and pathway analysys.
Avalos, Belinda Rene 
1.0 To obtain high quality and germline tissue from patients with myeloid hematologic malignancies in pre-malignant conditions. This material will be used for a variety of genetic analyses aimed at identification of novel mutations involved in the initiation and progression of these diseases.

1.0 To sequence AML genomes for the discovery of mutations or germline variants.

2.0 To identify inherited genetic polymorphisms or mutations in germline DNA that increase susc
Avalos, Belinda Rene 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.